Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine


Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Related Content